James Grant of Michigan BCBS summarized the frustration: "We were wasting millions of dollars, and people did not even see true benefit." From an actuarial perspective, the math was devastating
7 PCCA members with clinical services access may contact our Clinical Services team for help with microdosing GLP-1 RAs and other compounding concerns
(20) The control group experienced four times more BMC loss compared to the liraglutide group, with an approximate difference of 27g (95% CI: 5-48, p=.01)
In contrast to generic medicines which are exact copies of chemically synthesised branded drugs, biosimilars closely resemble the structure and function of their reference product and are produced in modified living organisms like yeast and bacteria
Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine
Lets take a look at the main ingredients and see what the studies do show, and what the connections are to GLP-1s
